文献速递系统性红斑狼疮

奥妥珠单抗B细胞清除治疗增殖性狼疮肾炎的随机双盲安慰剂对照试验

B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial.
PubMed 文献 · Ann Rheum Dis · 2021-10-06

该随机双盲安慰剂对照试验纳入125例接受霉酚酸酯和糖皮质激素治疗的狼疮肾炎患者,比较奥妥珠单抗(一种人源化II型抗CD20单克隆抗体)与安慰剂的疗效。第52周完全肾脏缓解率在奥妥珠单抗组为35%、安慰剂组为23%(差异12%,95%CI -3.4%至28%,p=0.115),第104周分别为41%和23%(差异19%,95%CI 2.7%至35%,p=0.026)。奥妥珠单抗未增加严重不良事件、严重感染或死亡,但非严重输注相关反应更常见。

要点

  • 第104周完全肾脏缓解率奥妥珠单抗组41% vs 安慰剂组23%,差异19%(95%CI 2.7%至35%,p=0.026)。
  • 第52周主要终点完全肾脏缓解率两组差异12%(95%CI -3.4%至28%,p=0.115),未达预设α水平0.2。
  • 奥妥珠单抗未增加严重不良事件、严重感染或死亡,非严重输注相关反应更常见。

核心结论

  • 在接受标准治疗的狼疮肾炎患者中,加用奥妥珠单抗至第104周可观察到肾脏缓解改善,且耐受性良好,未发现新的安全性信号。

研究设计与样本

  • 随机、双盲、安慰剂对照试验,纳入125例接受霉酚酸酯和糖皮质激素治疗的狼疮肾炎患者,随机接受奥妥珠单抗1000 mg或安慰剂(第1天及第2、24、26周给药),随访至第104周。

主要发现

  • 第52周完全肾脏缓解率奥妥珠单抗组22例(35%)vs 安慰剂组14例(23%),百分比差异12%(95%CI -3.4%至28%),p=0.115。
  • 第104周完全肾脏缓解率奥妥珠单抗组26例(41%)vs 安慰剂组14例(23%),百分比差异19%(95%CI 2.7%至35%),p=0.026。
  • 奥妥珠单抗在其他肾脏应答指标、血清学、估算肾小球滤过率和蛋白尿方面改善更明显。
  • 奥妥珠单抗未增加严重不良事件、严重感染或死亡,非严重输注相关反应更常见。

关键数值与推荐

  • 主要终点为第52周完全肾脏缓解率,预设α水平为0.2。
  • 奥妥珠单抗给药方案为1000 mg于第1天及第2、24、26周。

临床怎么用

  • 对于接受霉酚酸酯和糖皮质激素治疗的增殖性狼疮肾炎患者,加用奥妥珠单抗可能改善至第104周的肾脏缓解,且未增加严重不良事件、严重感染或死亡。
  • 需注意奥妥珠单抗组非严重输注相关反应更常见。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II anti-CD20 monoclonal antibody that induces potent B-cell depletion, with placebo for the treatment of LN in combination with standard therapies. METHODS: Patients with LN receiving mycophenolate and corticosteroids were randomised to obinutuzumab 1000 mg or placebo on day 1 and weeks 2, 24 and 26, and followed through week 104. The primary endpoint was complete renal response (CRR) at week 52. Exploratory analyses through week 104 were conducted. The prespecified alpha level was 0.2. RESULTS: A total of 125 patients were randomised and received blinded infusions. Achievement of CRR was greater with obinutuzumab at week 52 (primary endpoint, 22 (35%) vs 14 (23%) with placebo; percentage difference, 12% (95% CI -3.4% to 28%), p=0.115) and at week 104 (26 (41%) vs 14 (23%); percentage difference, 19% (95% CI 2.7% to 35%), p=0.026). Improvements in other renal response measures, serologies, estimated glomerular filtration rate and proteinuria were greater with obinutuzumab. Obinutuzumab was not associated with increases in serious adverse events, serious infections or deaths. Non-serious infusion-related reactions occurred more frequently with obinutuzumab. CONCLUSIONS: Improved renal responses through week 104 were observed in patients with LN who received obinutuzumab plus standard therapies compared with standard therapies alone. Obinutuzumab was well tolerated and no new safety signals were identified. TRIAL REGISTRATION NUMBER: NCT02550652.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Furie RA, Aroca G, Cascino MD, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2021. PMID: 34615636. doi:10.1136/annrheumdis-2021-220920

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。